HSD17B13 and metabolic disease: The identification of specific drugs targeting HLA-DRB5, GJB3, HSD17B13, and CD244 for various indications, such as cancer, metabolic diseases, and liver disorders, further strengthens their potential as therapeutic targets in LUAD.